RNA干扰疗法降低脂蛋白a的临床研究进展  

Clinical Research of RNA Interference Therapy in Reducing Lipoprotein(a)

作　　者：张小芳 张冬颖[1] ZHANG Xiaofang;ZHANG Dongying(Department of Cardiovascular Medicine,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China)

机构地区：[1]重庆医科大学附属第一医院心血管内科,重庆400000

出　　处：《心血管病学进展》2023年第7期622-626,共5页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金(81970203)。

摘　　要：由载脂蛋白(a)[apo(a)]和载脂蛋白B100(ApoB100)组成的脂蛋白a[Lp(a)]与心血管疾病残余风险相关,但目前临床上尚缺乏降低Lp(a)的有效药物。RNA干扰(RNAi)疗法可通过小干扰RNA或反义寡核苷酸干扰apo(a)或ApoB100 mRNA的翻译,减少Lp(a)合成。现就RNAi降低Lp(a)水平的临床研究进展进行综述。Lipoprotein(a)[Lp(a)],which is mainly composed of apolipoprotein(a)[apo(a)]and apolipoprotein B100(ApoB100),is associated with residual risk of cardiovascular disease,but there is no specific drug for reducing Lp(a)in clinical practice.RNA interference(RNAi)therapy can interfere the translation of apo(a)or ApoB100 mRNA through small interfering RNA(siRNA)or antisense oligonucleotides(ASO),resulting in decreased Lp(a)synthesis.This article reviews the clinical research progress of RNAi in reducing Lp(a).

关 键 词：RNA干扰疗法 小干扰RNA 反义寡核苷酸 脂蛋白A 

分 类 号：R54[医药卫生—心血管疾病]